LILY

Eli Lilly and Company BDR (LILY34)

Market Closed
5 Dec, 19:55
B3 B3
R$
182. 25
+3.24
+1.81%
R$
783.5T Market Cap
104.2 P/E Ratio
5.2% Div Yield
16,824 Volume
6.64 Eps
R$ 179.01
Previous Close
Day Range
179.71 184
Year Range
113 208.36
Want to track LILY34 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 58 days

Summary

LILY34 closed Friday higher at R$182.25, an increase of 1.81% from Thursday's close, completing a monthly decrease of -4.3% or R$8.19. Over the past 12 months, LILY34 stock gained 13.54%.
LILY34 pays dividends to its shareholders, with the most recent payment made on Jun 16, 2025.
The last earnings report, released on Oct 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 04, 2026.
Eli Lilly and Company BDR has completed 1 stock splits, with the recent split occurring on Nov 21, 2022.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on B3 (BRL).

LILY34 Chart

Similar

AstraZeneca PLC Sponsored BDR
R$ 81.52
+2.31%
Pfizer Inc.
R$ 35.46
+4.23%
Amgen Inc.
R$ 64.28
-0.62%
Gilead Sciences Inc.
R$ 331.32
0%
Cigna Group
R$ 365.8
0%

Eli Lilly and Company BDR (LILY34) FAQ

What is the stock price today?

The current price is R$182.25.

On which exchange is it traded?

Eli Lilly and Company BDR is listed on B3.

What is its stock symbol?

The ticker symbol is LILY34.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 5.2%.

What is its market cap?

As of today, the market cap is 783.5T.

When is the next earnings date?

The next earnings report will release on Feb 04, 2026.

Has Eli Lilly and Company BDR ever had a stock split?

Eli Lilly and Company BDR had 1 splits and the recent split was on Nov 21, 2022.

Eli Lilly and Company BDR Profile

Pharmaceuticals Industry
Healthcare Sector
David A. Ricks CEO
B3 Exchange
BRLILYBDR006 ISIN
US Country
47,000 Employees
14 May 2025 Last Dividend
- Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000